TY - JOUR
T1 - Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model
AU - Kim, Jae Ouk
AU - Kim, Dong Hyeon
AU - Chang, Woo Sung
AU - Hong, Changwan
AU - Park, Se Ho
AU - Kim, Sanghee
AU - Kang, Chang Yuil
N1 - Funding Information:
Supported by grant number FPR02A8-18-120 of the 21C Frontier Proteomics Project from the Korean Ministry of Science and Technology.
PY - 2004/12
Y1 - 2004/12
N2 - Allergic asthma is an inflammatory lung disease caused by a T H2-driven immune response. However, intranasal exposures to soluble antigen lead to mucosal tolerance, and the mechanism involved in generation of T H2 responses to inert inhaled allergens is unknown. The aim of this study was to investigate whether CD1d-restricted natural killer T (NKT) cells can contribute to the induction of T H2-dependent allergic asthma in a mouse model. To investigate the effect of NKT cells on the development of asthma, NKT cell ligand, α-galactosylceramide (αGC), was used with antigens. We intranasally sensitized Balb/c mice with various combinations of antigen and αGC for 3 consecutive days and challenged them 2 weeks later with an aerosol of ovalbumin. NKT cell-deficient or T H cell-deficient mice were immunized by administering ovalbumin and αGC together, and ovalbumin inhalation. Only when immunized with ovalbumin plus αGC, airway hyperreactivity, airway eosinophils, elevated IgE level, and T H2-cytokine production were observed in Balb/c mice. Ovalbumin alone, αGC alone, or BSA plus αGC-immunized mice did not induce asthma. Studies in NKT cell-deficient, or CD4 + T-cell-deficient mice intranasally exposed to ovalbumin plus αGC did not show the development of asthma. An increase of NKT cells in bronchoalveolar lavage was observed in the pathologic states. These data demonstrate that NKT cells can play crucial roles in allergen sensitization and pathologic states in asthma. Furthermore, our new asthma model using αGC will be very useful to induce asthma and to dissect the role of NKT cells and other cells in asthma.
AB - Allergic asthma is an inflammatory lung disease caused by a T H2-driven immune response. However, intranasal exposures to soluble antigen lead to mucosal tolerance, and the mechanism involved in generation of T H2 responses to inert inhaled allergens is unknown. The aim of this study was to investigate whether CD1d-restricted natural killer T (NKT) cells can contribute to the induction of T H2-dependent allergic asthma in a mouse model. To investigate the effect of NKT cells on the development of asthma, NKT cell ligand, α-galactosylceramide (αGC), was used with antigens. We intranasally sensitized Balb/c mice with various combinations of antigen and αGC for 3 consecutive days and challenged them 2 weeks later with an aerosol of ovalbumin. NKT cell-deficient or T H cell-deficient mice were immunized by administering ovalbumin and αGC together, and ovalbumin inhalation. Only when immunized with ovalbumin plus αGC, airway hyperreactivity, airway eosinophils, elevated IgE level, and T H2-cytokine production were observed in Balb/c mice. Ovalbumin alone, αGC alone, or BSA plus αGC-immunized mice did not induce asthma. Studies in NKT cell-deficient, or CD4 + T-cell-deficient mice intranasally exposed to ovalbumin plus αGC did not show the development of asthma. An increase of NKT cells in bronchoalveolar lavage was observed in the pathologic states. These data demonstrate that NKT cells can play crucial roles in allergen sensitization and pathologic states in asthma. Furthermore, our new asthma model using αGC will be very useful to induce asthma and to dissect the role of NKT cells and other cells in asthma.
KW - Natural killer T cell
KW - asthma
KW - α-galactosylceramide
UR - http://www.scopus.com/inward/record.url?scp=9644279528&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2004.09.004
DO - 10.1016/j.jaci.2004.09.004
M3 - Article
C2 - 15577831
AN - SCOPUS:9644279528
SN - 0091-6749
VL - 114
SP - 1332
EP - 1338
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -